Drugs / IBI3001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06349408 | Jan 2025 → Dec 2026 expected | — | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting innoventbio.com ↗
IBI3001 showed strong anti-tumor efficacy in vitro and in vivo across multiple solid tumors and is well tolerated with the therapeutic index at 40. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06349408 ↗ |
| Route | Intravenous | “IBI3001 is proposed to be administered by intravenous infusion (IV)” NCT06349408 ↗ |